Fabrication of Synthetic Mesenchymal Stem Cells for the Treatment of Acute Myocardial Infarction in Mice

Circulation Research

Volumn 120, Issue 11, 2017, Pages 1768-1775

  Luo, Lan ^a   Tang, Junnan ^c,d,e   Nishi, Kodai ^b   Yan, Chen ^a   Dinh, Phuong Uyen ^d,e   Cores, Jhon ^d,e   Kudo, Takashi ^b   Zhang, Jinying ^c   Li, Tao Sheng ^a   Cheng, Ke ^d,e,f  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

^c THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^d Department of Molecular Biomedical Sciences and Comparative Medicine Institute ^*  (China)

^e NORTH CAROLINA STATE UNIVERSITY   (United States)

^f UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

artificial cells; mesenchymal stem cells; myocardial infarction; regeneration; stem cells; tissue engineering

Indexed keywords

ACTIN; CD31 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; ENDOGLIN; MEMBRANE ANTIGEN; POLYGLACTIN; SOMATOMEDIN C; STROMAL CELL DERIVED FACTOR 1; THY 1 ANTIGEN; VASCULOTROPIN; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ACUTE HEART INFARCTION; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CARDIAC MUSCLE CELL; CELL ENCAPSULATION; CONTROLLED STUDY; CRYOPRESERVATION; FREEZE DRYING; HEART FUNCTION; HEART LEFT VENTRICLE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MATERIAL COATING; MEMBRANE MICROPARTICLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYNTHETIC BIOLOGY; THERAPY EFFECT; TISSUE ENGINEERING; ANIMAL; C57BL MOUSE; CELL CULTURE; DIAGNOSTIC IMAGING; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; SECRETION (PROCESS); TREATMENT OUTCOME;

ANIMALS; CELLS, CULTURED; HUMANS; LACTIC ACID; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; POLYGLYCOLIC ACID; POSITRON-EMISSION TOMOGRAPHY; TREATMENT OUTCOME;

EID: 85015637764     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.310374     Document Type: Article

References (26)

1. Segers VF, Lee RT. Stem-cell therapy for cardiac disease. Nature. 2008;451:937-942. doi: 10.1038/nature06800.
2. Karantalis V, Hare JM. Use of mesenchymal stem cells for therapy of cardiac disease. Circ Res. 2015;116:1413-1430. doi: 10.1161/ CIRCRESAHA.116.303614.
3. Squillaro T, Peluso G, Galderisi U. Clinical trials with mesenchymal stem cells: an update. Cell Transplant. 2016;25:829-848. doi: 10.3727/096368915X689622.
4. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002;105:93-98.
5. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res. 2008;103:1204-1219. doi: 10.1161/ CIRCRESAHA.108.176826.
6. Lai RC, Arslan F, Lee MM, Sze NS, Choo A, Chen TS, Salto-Tellez M, Timmers L, Lee CN, El Oakley RM, Pasterkamp G, de Kleijn DP, Lim SK. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res. 2010;4:214-222. doi: 10.1016/j.scr.2009.12.003.
7. Angoulvant D, Ivanes F, Ferrera R, Matthews PG, Nataf S, Ovize M. Mesenchymal stem cell conditioned media attenuates in vitro and ex vivo myocardial reperfusion injury. J Heart Lung Transplant. 2011;30:95-102. doi: 10.1016/j.healun.2010.08.023.
8. Boomsma RA, Geenen DL. Mesenchymal stem cells secrete multiple cytokines that promote angiogenesis and have contrasting effects on chemotaxis and apoptosis. PLoS One. 2012;7:e35685. doi: 10.1371/journal. pone.0035685.
9. Beohar N, Rapp J, Pandya S, Losordo DW. Rebuilding the damaged heart: the potential of cytokines and growth factors in the treatment of ischemic heart disease. J Am Coll Cardiol. 2010;56:1287-1297. doi: 10.1016/j. jacc.2010.05.039.
10. Baraniak PR, McDevitt TC. Stem cell paracrine actions and tissue regeneration. Regen Med. 2010;5:121-143. doi: 10.2217/rme.09.74.
11. Lai RC, Chen TS, Lim SK. Mesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease. Regen Med. 2011;6:481-492. doi: 10.2217/rme.11.35.
12. Ibrahim AG, Cheng K, Marbán E. Exosomes as critical agents of cardiac regeneration triggered by cell therapy. Stem Cell Reports. 2014;2:606-619. doi: 10.1016/j.stemcr.2014.04.006.
13. Vandergriff AC, de Andrade JB, Tang J, Hensley MT, Piedrahita JA, Caranasos TG, Cheng K. Intravenous cardiac stem cell-derived exosomes ameliorate cardiac dysfunction in doxorubicin induced dilated cardiomyopathy. Stem Cells Int. 2015;2015:960926. doi: 10.1155/2015/960926.
14. Gray WD, French KM, Ghosh-Choudhary S, Maxwell JT, Brown ME, Platt MO, Searles CD, Davis ME. Identification of therapeutic covariant microRNA clusters in hypoxia-treated cardiac progenitor cell exosomes using systems biology. Circ Res. 2015;116:255-263. doi: 10.1161/ CIRCRESAHA.116.304360.
15. Khan M, Nickoloff E, Abramova T, et al. Embryonic stem cell-derived exosomes promote endogenous repair mechanisms and enhance cardiac function following myocardial infarction. Circ Res. 2015;117:52-64. doi: 10.1161/CIRCRESAHA.117.305990.
16. Emanueli C, Shearn AI, Angelini GD, Sahoo S. Exosomes and exosomal miRNAs in cardiovascular protection and repair. Vascul Pharmacol. 2015;71:24-30. doi: 10.1016/j.vph.2015.02.008.
17. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGAbased nanoparticles: an overview of biomedical applications. J Control Release. 2012;161:505-522. doi: 10.1016/j.jconrel.2012.01.043.
18. Tang J, Shen D, Caranasos TG, Wang Z, Vandergriff AC, Allen TA, Hensley MT, Dinh PU, Cores J, Li TS, Zhang J, Kan Q, Cheng K. Therapeutic microparticles functionalized with biomimetic cardiac stem cell membranes and secretome. Nat Commun. 2017;8:13724. doi: 10.1038/ncomms13724.
19. Fang RH, Hu CM, Luk BT, Gao W, Copp JA, Tai Y, O'Connor DE, Zhang L. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett. 2014;14:2181-2188. doi: 10.1021/nl500618u.
20. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007;110:3499-3506. doi: 10.1182/ blood-2007-02-069716.
21. Xie Y, Ibrahim A, Cheng K, Wu Z, Liang W, Malliaras K, Sun B, Liu W, Shen D, Cheol Cho H, Li T, Lu L, Lu G, Marbán E. Importance of cellcell contact in the therapeutic benefits of cardiosphere-derived cells. Stem Cells. 2014;32:2397-2406. doi: 10.1002/stem.1736.
22. Jaffer FA, Libby P, Weissleder R. Molecular imaging of cardiovascular disease. Circulation. 2007;116:1052-1061. doi: 10.1161/ CIRCULATIONAHA.106.647164.
23. Tsui BM, Kraitchman DL. Recent advances in small-animal cardiovascular imaging. J Nucl Med. 2009;50:667-670. doi: 10.2967/ jnumed.108.058479.
24. Ghesani M, Depuey EG, Rozanski A. Role of F-18 FDG positron emission tomography (PET) in the assessment of myocardial viability. Echocardiography. 2005;22:165-177. doi: 10.1111/j.0742-2822.2005.04032.x.
25. Abidov A, Germano G, Hachamovitch R, Slomka P, Berman DS. Gated SPECT in assessment of regional and global left ventricular function: an update. J Nucl Cardiol. 2013;20:1118-43; quiz 1144. doi: 10.1007/ s12350-013-9792-1.
26. Tang JM, Wang JN, Zhang L, Zheng F, Yang JY, Kong X, Guo LY, Chen L, Huang YZ, Wan Y, Chen SY. VEGF/SDF-1 promotes cardiac stem cell mobilization and myocardial repair in the infarcted heart. Cardiovasc Res. 2011;91:402-411. doi: 10.1093/cvr/cvr053.